Lung cancer is the leading cause of cancer mortality worldwide. During the past quarter of a century, there have been definite steps forward in understanding the biology of this disease. However, progress in the treatment of advanced non-small-cell lung cancer (NSCLC) has been more elusive and has not been associated with a realistic probability of long-term survival. For this disease, platinum-based chemotherapy is currently the standard treatment. Numerous studies have compared various platinum doublets and have concluded that all such combinations are comparable in their clinical efficacy. Moreover, several trials evaluating different chemotherapy regimens in NSCLC have failed to document a difference based on histology. Recent evidence suggests that histology represents an important variable in the decision making. This review will discuss this new evidence in the first-line treatment of advanced NSCLC, focusing on different possible therapeutic approaches according to histologic subtype. © 2009 Expert Reviews Ltd.

First-line treatment in advanced non-small-cell lung cancer: The emerging role of the histologic subtype / Tiseo, M.; Bartolotti, M.; Gelsomino, F.; Ardizzoni, A.. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - 9:4(2009), pp. 425-435. [10.1586/ERA.09.3]

First-line treatment in advanced non-small-cell lung cancer: The emerging role of the histologic subtype

Tiseo M.;
2009-01-01

Abstract

Lung cancer is the leading cause of cancer mortality worldwide. During the past quarter of a century, there have been definite steps forward in understanding the biology of this disease. However, progress in the treatment of advanced non-small-cell lung cancer (NSCLC) has been more elusive and has not been associated with a realistic probability of long-term survival. For this disease, platinum-based chemotherapy is currently the standard treatment. Numerous studies have compared various platinum doublets and have concluded that all such combinations are comparable in their clinical efficacy. Moreover, several trials evaluating different chemotherapy regimens in NSCLC have failed to document a difference based on histology. Recent evidence suggests that histology represents an important variable in the decision making. This review will discuss this new evidence in the first-line treatment of advanced NSCLC, focusing on different possible therapeutic approaches according to histologic subtype. © 2009 Expert Reviews Ltd.
2009
First-line treatment in advanced non-small-cell lung cancer: The emerging role of the histologic subtype / Tiseo, M.; Bartolotti, M.; Gelsomino, F.; Ardizzoni, A.. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - 9:4(2009), pp. 425-435. [10.1586/ERA.09.3]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2862143
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 26
social impact